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Abstract
Background—A rigorous comparison of cervical cancer screening methods utilizing data on
immune status, antiretroviral therapy (ART) and colposcopy-directed biopsy has not been
performed among HIV-positive women.
Methods—Between June and November 2009, 500 HIV-positive women were enrolled at an
HIV treatment clinic in Nairobi, Kenya, and underwent Papanicolau (Pap) smear, visual inspection
with acetic acid (VIA), human papillomavirus (HPV) and colposcopy-directed biopsy (gold
standard). Positive Pap smear (ASCUS+, LSIL+, HSIL+), VIA, HPV and their combinations were
compared with CIN2/3+. Sensitivity, specificity and AUC (sensitivity and 1–specificity) were
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compared using pairwise tests and multivariate logistic regression models that included age, CD4+
cell count and ART duration.
Results—Of 500 enrolled, 498 samples were collected. On histology, there were 172 (35%)
normal, 186 (37%) CIN1, 66 (13%) CIN2, 47 (9%) CIN3 and 27 (5%) indeterminate. Pap
(ASCUS+) was the most sensitive screening method (92.7%), combination of both Pap (HSIL+)
and VIA positive was the most specific (99.1%) and Pap (HSIL+) had the highest AUC (0.85). In
multivariate analyses, CD4+ cell count of 350 cells/μl or less was associated with decreased HPV
specificity (P = 0.002); ART duration of less than 2 years was associated with decreased HPV (P
= 0.01) and VIA (P = 0.03) specificity; and age less than 40 years was associated with increased
VIA sensitivity (P < 0.001) and decreased HPV specificity (P = 0.005).
Conclusion—Pap smear is a robust test among HIV-positive women regardless of immune
status or ART duration. Results should be cautiously interpreted when using HPV among those
younger, immunosuppressed or on ART less than 2 years, and when using VIA among those aged
40 years or more.
Keywords
cervical cancer screening; HIV-1; human papillomavirus; Papanicolau smear; visual inspection
with acetic acid
Introduction
Cervical cancer is the second most frequently diagnosed cancer among women worldwide
with the highest incidence taking place in resource-limited countries, particularly in sub-
Saharan Africa where approximately 75 000 new cases occur each year [1]. Sub-Saharan
Africa is also home to 22.9 million HIV-infected people [2]. The proximity of these two
diseases highlights the need to understand how HIV infection and its treatment may interact
with the detection of cervical cancer.
There are several common cervical cancer screening methods available to HIV-positive
women in resource-limited settings including the Papanicolaou test (Pap smear), visual
inspection of the cervix with acetic acid (VIA) and human papillomavirus (HPV) testing.
Among HIV-positive women, these methods have not been compared together and in
combination against the gold standard of colposcopy-directed biopsy while examining an
association with immunodeficiency or use of antiretroviral therapy (ART). Given the
relationship between HIV and HPV infection, HPV and the duration of ART use, and the
development of cervical intraepithelial neoplasia (CIN) and AIDS [3–7], it is reasonable to
hypothesize that the test characteristics of these methods may vary according to immune
status and length of ART exposure.
A rigorous comparison between these cervical screening methods is relevant in sub-Saharan
Africa where large-scale HIV treatment programmes provide chronic medical care for an
expanding number of HIV-positive women. As antiretroviral treatment programmes in this
region are successfully rolled out and extending the lives of HIV-positive women, cervical
cancer screening is being considered as an effective measure to reduce unnecessary
morbidity and mortality in the population [8]. An important question for many of these
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donor-funded HIV programmes is what cervical cancer screening method or combination of
methods should be implemented and how should results be interpreted in relation to
immunodeficiency or ART use.
Using data on histology from colposcopy-directed biopsy, CD4+ cell count and duration of
ART exposure, the objective of this study was to determine the sensitivity, specificity and
positive predictive value (PPV) and negative predictive value (NPV) of Pap smear, VIA,
HPV and their combinations among HIV-positive women.
Materials and methods
Study setting
The trial was conducted at the Cope Hope Center for Infectious Diseases in Nairobi, Kenya,
between June and November, 2009. Funded by the President's Emergency Plan for AIDS
Relief (PEPFAR), the Hope Center provides free ART to HIV-positive adults and children
[9] and is administered by the Coptic Orthodox Mission with support from the University of
Washington [10]. HIV-positive women enrolled at the Hope Center were seen during routine
medical follow-up and referred to an adjacent research clinic for information on cervical
cancer screening. Five hundred HIV-positive women were invited to participate and were
eligible if they were between 18 and 55 years of age, had an intact cervix, were HIV-
positive and never had cervical treatment for cancerous or pre-cancerous lesions. The study
protocol was reviewed and approved by the institutional review boards at the University of
Washington (Seattle, Washington, USA), Kenyatta National Hospital (Nairobi, Kenya) and
the International Agency for Research on Cancer (IARC; Lyon, France).
Enrolment and study procedures
Upon enrolment in the study and after informed consent, participants had blood drawn for
CD4+ cell count (FACSCount; Becton Dickinson, Franklin Lakes, New Jersey, USA) and
provided information on sociodemographic and clinical characteristics. Further data
regarding the participant's HIV medical and ART history were obtained from Hope Center
medical records. During the subsequent pelvic examination, a Pap smear was performed in
which a Cervex brush was inserted into the endocervical canal, smeared on a glass slide and
fixed (Andwin Scientific Safetex NO-TOUCH Pap kit; Addison, Illinois, USA). The same
Cervex brush was then stirred in PreservCyt media (Hologic, Marlborough, Massachusetts,
USA) that was later analysed for HPV.
VIA was subsequently performed by the study nurse who had received over 2 weeks of
hands-on training in VIA and had over 6 months of work experience conducting VIA prior
to study initiation. After the application of 5% acetic acid to the cervix for 2 min, VIA was
considered positive if there was a well-defined, distinct acetowhite lesion close to the
squamocolumnar junction. The examination was considered unsatisfactory if the
squamocolumnar junction could not be fully visualized. After VIA, all women underwent
colposcopy by the study doctor who took a single biopsy at the site of any visualized lesion
or at 12 o'clock on the cervix if no lesion was seen, and placed the specimen in 10%
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buffered formalin. The study doctor who performed the colposcopy was blinded to the VIA
results obtained by the study nurse.
Pap smears and biopsies were prepared and processed by laboratory technologists and read
by the study pathologist from Aga Khan Medical University, who reported cytology results
according to the Bethesda 1991 revised classification scheme and histology results
according to the Richart CIN staging system [11,12]. Samples prepared for reading had all
identifying information removed and were given unique numbering systems by laboratory
assistants that blinded the study pathologist to the identities of the participants and their
samples. Pap smear and biopsy samples were read by the study pathologist at times
separated by at least 2 days and each had their own separate numbering systems that could
not be matched by the pathologist. Histology results based on colposcopy-directed biopsy
provided the gold standard final diagnosis in this study.
Participants who were diagnosed as having CIN2 or CIN3 on biopsy were offered
cryotherapy treatment. Those who were ineligible to receive cryotherapy were referred for
subsidized care at a neighbouring government medical facility where they were treated with
loop electrosurgical excision procedure (LEEP).
Laboratory methods
PreservCyt media was stored in Nairobi at ambient temperatures of 25°C or less before
being shipped to the IARC in Lyon, France, and from there to Vrije Universiteit (VU)
Medical Center in Amsterdam, the Netherlands. At the VU Department of Pathology, HPV
DNA testing was performed on exfoliated cells [13]. Beta-globin PCR analysis was
performed in order to assess the quality of the HPV DNA, and DNA was determined using
general primer GP5+/6+-mediated PCR [14]. PCR products were hybridized using an
enzyme immunoassay (EIA) that included an oligoprobe for high-risk HPV types. The high-
risk HPV types included 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Samples
that were positive on EIA for high-risk HPV types were considered HPV positive [7].
Statistical methods
Sociodemographic and clinical data were collected and recorded on paper forms that were
scanned into a computer database using TeleForm software (Autonomy Cardiff, Vista,
California, USA). Sensitivity, specificity, PPV, NPV and area under the curve (AUC) for
sensitivity and 1-specificity were calculated using colposcopy-directed biopsy histology
results as the gold standard. Test positivity was calculated by taking the number of positive
results for each screening method and dividing by the total number of samples tested.
Sensitivity, specificity and AUC were formally compared pairwise using McNemar's test
and DeLong's test of AUC [15]. Comparisons of sensitivity and specificity were further
stratified by age (<40 years and ≥40 years), duration of ART use (none, ART <2 years and
ART ≥2 years) and CD4+ cell count (≤350 and >350 cells/μl), and were compared using chi-
square tests and logistic regression. Sensitivity and specificity found to be statistically
significantly different for varying strata of age, CD4+ cell count or duration on ARTon a
univariate basis were further assessed in multivariate logistic regression models that
included all three of these covariates.
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Cytology results were presented using three different definitions of positive results: ASCUS
+, which included ASCUS (atypical squamous cells +of undetermined significance), LSIL
(low-grade squamous intraepithelial lesions), HSIL (high-grade squamous intraepithelial
lesions) and AGC (atypical glandular cells); LSIL+, which included LSIL, HSIL and AGC;
and HSIL+, which included HSIL and AGC. Positive histology results were defined as
CIN2/3, which contained CIN2 or more severe findings.
Screening methods were compared with histology individually and in combination with each
other. Dual combinations included VIA with HPV, VIA with Pap smear and Pap smear with
HPV. In dual combinations, a positive result was defined as both tests (’plus’) being positive
or either test (’or’) being positive.
All statistical analyses were performed using IBM SPSS version 20.0 (IBM Corp., Armonk,
New York, USA) and STATA version 12.1 (StataCorp LP, College Station, Texas, USA).
Results
Study population
Of the 500 women enrolled in the study, 498 underwent successful sample collection. The
median age of the study population was 38 years and 45% were between the ages of 30 and
39 years (Table 1). Nearly half (43%) of the participants were married, and 51% had at least
a secondary school education. Most women (77%) were employed, none reported any
smoking history and 25% reported having three or more lifetime sexual partners.
The median CD4+ cell count at the time of cervical cancer screening was 371 cells/μl
[interquartile range (IQR), 245–533] and the median weight was 65 kg (IQR, 57–74). Two
hundred and twenty-nine women (46%) had a CD4+ cell count of 350 cells/μl or less. Three
hundred and seventy-seven women (75%) were on ART at the time of cervical screening,
and 182 (48%) of these women had been on ART for at least 2 years. Those on ART had
been taking medications for a median duration of 797 days (IQR, 330–1210).
Cervical cancer screening results by method
On the basis of colposcopy-directed biopsy, 172 (35%) of the participants were classified as
normal, 186 (37%) had CIN1, 66 (13%) CIN2, 47 (9%) CIN3 and 27 (5%) were
indeterminate (Table 2). There were no invasive cancers noted on biopsy among the 498
HIV-positive women screened. On Pap smear, 187 (38%) were normal, 77 (15%) had
ASCUS, 121 (24%) LSIL, 92 (18%) HSIL, 2 (0.4%) AGC and 19 (4%) were indeterminate.
On VIA, 296 (59%) were negative, 197 (40%) were positive and 5 (1%) were indeterminate.
On HPV, 234 (47%) were negative and 264 (53%) were positive.
Sensitivity, specificity and area under the curve
Individually, the most sensitive test was Pap (ASCUS+) (92.7%), which was significantly
more sensitive than VIA (62.7%; P < 0.001), Pap (HSIL+) (71.8%; P < 0.001) and HPV
(83.6%; P = 0.04) (Table 3). HPV was significantly more sensitive than VIA (P < 0.001)
and Pap (HSIL+) (P = 0.04). Pap (HSIL+) (97.1%) was significantly more specific than VIA
(65.9%; P < 0.001) and HPV (55.7%; P < 0.001), and VIA was more specific than HPV (P
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= 0.006). The cervical screening method with the highest AUC was Pap (HSIL+) (0.85),
which was significantly greater than VIA (0.64; P < 0.001), HPV (0.70; P < 0.001), Pap
(ASCUS+) (0.71; P < 0.001) and Pap (LSIL+) (0.76; P < 0.001) (Table 3).
Combining cervical screening methods did not significantly improve test sensitivity over
using Pap (ASCUS+) alone. However, combining VIA and Pap (HSIL+) to confirm positive
test results had greater specificity than Pap (HSIL+) alone (99.1 vs. 97.1%; P < 0.001).
Combining tests to confirm positive test results with Pap (HSIL+) improved the AUC of
VIA and HPV but was not significantly greater than using Pap (HSIL+) alone (Table 3).
Using VIA as a general screening tool followed by a confirmatory Pap (HSIL+) or HPV of
all VIA positives (’both test positive’) significantly increased the AUC of using VIA from
0.64 to 0.75 (P < 0.001) and 0.71 (P < 0.001), respectively. HPV followed by confirmatory
positive Pap (HSIL+) increased AUC from 0.70 to 0.81 (P < 0.001); however, combining
HPV and VIA made no significant difference compared with HPV alone (0.70 vs. 0.71; P =
0.6).
Association with immune status, duration of antiretroviral exposure and age
The specificity of HPV was significantly decreased at younger ages, lower CD4+ cell counts
and after little or no ART exposure (Table 4). The specificity of HPV at CD4+ cell counts of
350 cells/μl or less was significantly less than at CD4+ cell counts of more than 350 cells/μl
(45.7 vs. 63.5%; P < 0.001) and among women less than 40 years of age compared to at
least 40 years of age (50.0 vs. 65.1%; P = 0.006) (Table 4). Compared with women with at
least 2 years of ART exposure, those women with no ART (66.2 vs. 51.5%, P = 0.03) and
those with less than 2 years of ART (66.2 vs. 45.5%, P < 0.001) had lower HPV specificity
(Tables 4 and 5). In multivariate analysis, age less than 40 years (P = 0.005), CD4+ cell
count of 350 cells/μl or less (P = 0.002) and ART less than 2 years (P = 0.01) remained
significantly associated with decreased HPV specificity suggesting the independent effects
of these covariates (Table 5).
The sensitivity of VIA was significantly decreased among women at least 40 years of age
compared with those less than 40 years of age (47.3 vs. 78.2%; P < 0.001), and this
association was independent of CD4+ cell count and duration of ART exposure (P < 0.001)
(Tables 4 and 5). VIA specificity did not differ significantly between not being on ART and
being on ART for at least 2 years (P = 0.3) (Table 5). However, VIA specificity was
significantly decreased among those on ART for less than 2 years compared with those on
ART for at least 2 years (57.3 vs. 72.5%; P = 0.01), and this association was independent of
age and CD4+ cell count (P = 0.03, Table 5).
Although the difference in Pap (HSIL+) specificity between women aged less than 40 years
and at least 40 years was on the edge of statistical significance (98.6 vs. 94.6%; P = 0.05), it
was not found to be statistically significant in a multivariate analysis that included CD4+ cell
count and duration of ART use (P = 0.07) (Tables 4 and 5).
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Discussion
This study of HIV-positive women in Kenya compared three cervical cancer screening
methods, Pap smear, VIA and HPV testing, with the gold standard of colposcopy-directed
biopsy. In this comparison, Pap (ASCUS+) had the highest sensitivity, combination of both
Pap (HSIL+) and VIA positive had the highest specificity and Pap (HSIL+) had the highest
AUC. Immunosuppression and younger age were independently associated with decreased
HPV specificity, while shorter exposure to ART was significantly associated with decreased
HPV and VIA specificity. Finally, older age was significantly associated with decreased
VIA sensitivity.
The high accuracy of Pap smear in this study confirms the utility of this standard test among
HIV-positive women [16,17]. Given access to readings by experienced and highly trained
pathologists, Pap (HSIL+) with its high AUC could be considered the best combination of
sensitivity and specificity among the individual screening methods tested. Pap (HSIL+) was
also the most specific test of the individual screening methods that were compared, whereas
Pap (ASCUS+) was the most sensitive. The sensitivity and specificity of Pap smear
remained unchanged regardless of immune status or duration of exposure to ART,
suggesting the robustness of this test among HIV-positive women compared with HPV and
VIA.
VIA has long been used as an economical alternative to Pap smear in a ‘see-and-treat’
approach with cryotherapy [18], and in this study, VIA among HIV-positive women had a
sensitivity of 62.7% and a specificity of 65.9%. These results are comparable to the
performance of VIA among HIV-negative women [19] and suggest that VIA may be a
reasonable cervical cancer screening choice among HIV-positive women in resource-limited
settings wherein cervical cancer screening is typically offered once in a lifetime and usually
without affordable alternatives [20–22]. Another similarity to VIA among HIV-negative
women is that the sensitivity of VIA was significantly decreased among HIV-positive
women who were at least 40 years of age [23,24]. Decreased VIA sensitivity at older ages
may reflect the reduced ability of visual inspection to detect changes in the transformation
zone, which retreats into the endocervical canal among postmenopausal women [25].
The sensitivity and specificity of VIA did not significantly differ according to immune
status. There was no significant difference in VIA sensitivity and specificity between
women who had CD4+ cell counts of 350 or less and more than 350 cells/μl. However,
shorter duration of ART exposure was found to be associated with decreased VIA
specificity. Although there was no significant difference between being off ART and on
ART for at least 2 years, there was a significant difference in VIA specificity between being
on ART for less than 2 years and on ART for at least 2 years, which was independent of age
and immune status. The reason for this finding is not clear and merits further investigation,
as this appears to be the first time this association has been reported in the literature.
Methods have recently been developed to batch test high-risk HPV types quickly and
cheaply making cervical cancer screening with HPVa potentially feasible option in resource-
limited settings in the near future [26,27]. Similar to results found among HIV-negative
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women, HPV testing among HIV-positive women in this study was sensitive but less
specific compared with other cervical cancer screening methods [28]. Therefore, the strength
of HPV testing among HIV-positive women may be in its combined use with VIA or Pap
smear. Confirming a positive VIA with HPV significantly increased the overall test
effectiveness of using VIA alone. Similarly, confirming a positive HPV with Pap (HSIL+)
significantly increased the overall test effectiveness of HPV alone.
Combining cervical screening methods may be useful in resource-limited settings such as
sub-Saharan Africa where most screening programmes at HIV clinics require donor funding
to provide these services to their catchment population. For example, in order to maximize
the number of HIV-positive women screened effectively with a fixed amount of funding, an
HIV treatment programme could consider offering inexpensive VIA to all women enrolled
in the clinic and only offer more expensive Pap smear screening to the more limited number
who are VIA positive. This would be less costly to the programme than offering Pap smear
to all women, and the overall test effectiveness of combining these tests, as this study
demonstrates, is better than VIA alone. Although conducting a comprehensive cost-
effectiveness analysis is beyond the scope of this manuscript, our data contribute important
information to future estimates of cost-effectiveness of cervical cancer screening among
HIV-positive women [29–32].
There are several challenges to using HPV alone to screen HIV-positive women for cervical
cancer. Immunodeficiency and shorter exposure to ART were each independently associated
with decreased HPV specificity.
Although immunodeficiency is associated with increased detection of HPV and cervical
dysplasia [7,33–35], our findings suggest that a significant amount of detectable HPV at
lower CD4+ cell counts is not associated with biopsy-proven disease. A reason may be the
lag between the detection of HPV, which immunodeficiency may promote, and the
development of CIN as represented by CIN2/3. The use of ART has been related to
increased regression of CIN lesions [36–40] and may enhance HPV clearance from the
cervix [7,41]. A recent study by Konopnicki et al. [6] found that sustained HIV viral
suppression on ART was significantly associated with a decreased risk of persistent HPV
infection that was independent of CD4+ cell count. These results correlate with a positive
association with ART exposure that was found in this study.
Decreased HPV specificity among HIV-positive women was also independently associated
with age less than 40 years. This is consistent with the knowledge that the peak incidence of
HPV infection occurs before 30 years of age and subsequently declines among HIV-
negative women [42,43], whereas the peak of CIN occurs 5–15 years later [44]. For this
reason, it is recommended in the United States to restrict HPV screening to women who are
more than 30 years of age [45]. Our study suggests that similar age restrictions should apply
to HIV-positive women.
In addition to having histology on all women as the gold standard comparison and a
relatively large sample size of HIV-positive women, this study's strengths included detailed
ART history and CD4+ cell count data. However, there are several study weaknesses. The
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Pap smears were read by a highly trained and experienced professor of pathology at a major
urban university in Kenya, and had a sensitivity and specificity that was better than those
found in similar studies among HIV-positive women in resource-limited settings [46–48].
As a result, our cytology results may be less replicable in many resource-limited countries
and demonstrate the importance of good pathology training and laboratory support. The
study was able to determine the association between test characteristics and the duration of
ART exposure, and it did not include the duration of immunosuppression, HPV infection
and cervical intraepithelial neoplastic disease. Consequently, some of these findings may not
capture the interaction between examined covariates and the evolution of HPV infection and
cervical disease over time.
A judicious interpretation of the findings from this cross-sectional study is required. Given
the robust performance of Pap smear in this investigation, it is recommended that Pap smear
be used among HIV-positive women when read in a well supported laboratory with good
quality control. This study reinforces the use of Pap smear among HIV-positive women in
resource-rich countries, but its results do not necessarily extrapolate to resource-constrained
settings wherein laboratory facilities, training and support may be limited. The best results
from HPV and VIA arise when they are used in combination with each other or with a good
quality Pap smear, and these combinations could be used to help resource-constrained HIV
treatment programmes screen a large patient population less expensively compared with
offering Pap smears to all women. HPV is a highly sensitive test and a valuable objective
screening tool, but positive results should be cautiously interpreted among HIV-positive
women who are younger, immunocompromised or have been on little or no ART. Finally,
the use of VIA among HIV-positive is similar to that among HIV-negative women and
should be used in comparable situations when other screening alternatives are unavailable
and/or unaffordable and among women less than 40 years of age [49].
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Table 1
Baseline characteristics.
Characteristics N N or Median (% or IQR)
Age (years) 500 38 (3–43)
Age groups (years) 500
    18–29 62 (12%)
    30–39 225 (45%)
    40–49 177 (35%)
    ≥50 36 (7%)
CD4+ cell count (cells/μl) 498
    ≤200 81 (16%)
    >200 and ≤350 148 (30%)
    >350 and ≤500 128 (26%)
    >500 141 (28%)
CD4+ cell count (cells/μl) 498 371 (245–533)
Weight (kg) 493 65 (57–74)
BMI (kg/m2) 482
    <18.5 13 (3%)
    18.5–24.9 208 (43%)
    25.0–29.9 165 (34%)
    ≥30 96 (20%)
WHO stage 496
    I 161 (33%)
    II 138 (28%)
    III 165 (33%)
    IV 32 (6%)
Marital status 500
    Married 215 (43%)
    Single 118 (24%
    Divorced/separated 77 (15%)
    Widowed 90 (18%)
Education level 500
    None 13 (2%)
    Primary 94 (19%)
    Secondary 254 (51%)
    College 139 (28%)
Employment 500
    Employed 383 (77%)
    Unemployed 117 (23%)
On ART 500
    Yes 377 (75%)
    No 123 (25%)
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Characteristics N N or Median (% or IQR)
Previous cervical screening 500 252 (50%)
Duration on ART (days) 377 797 (330–1210)
Smoking history 500
    No 500 (100%)
No. of lifetime sexual partners 387
    1 162 (42%)
    2 130 (34%)
    ≥3 95 (25%)
ART, antiretroviral therapy;IQR, interquartile range.
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Table 2
Papanicolaou smear, visual inspection with acetic acid and human papillomavirus testing of high-risk types
compared with histology results from colposcopy-directed biopsy.
Colposcopy-directed biopsy
N (%) Normal CIN 1 CIN 2 CIN 3 Indeterminate
Pap
    No dysplasia 187 38% 140 31 5 3 8
    ASCUS 77 15% 16 46 6 2 7
    LSIL 121 24% 7 95 11 4 4
    HSIL 92 18% 2 8 41 38 3
    AGC 2 0.4% 1 1 0 0 0
    Indeterminate 19 4% 6 5 3 0 5
    Total 498 100% 172 (35%) 186 (37%) 66 (13%) 47 (9%) 27 (5%)
VIA
    Negative 296 59% 118 117 28 14 19
    Positive 197 40% 54 65 38 33 7
    Indeterminate 5 1% 0 4 0 0 1
    Total 498 100% 172 (35%) 186 (37%) 66 (13%) 47 (9%) 27 (5%)
HPV
    Negative 234 47% 100 101 16 3 14
    Positive 264 53% 72 85 50 44 13
    Total 498 100% 172 (35%) 186 (37%) 66 (13%) 47 (9%) 27 (5%)
AGC, atypical glandular cells; ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HPV, human
papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; Pap, Papanicolau; VIA, visual
inspection with acetic acid.
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Table 3
Sensitivity, specificity, area under the curve of sensitivity and 1–specificity, positive predictive value, negative
predictive value and test positivity of screening methods individually and in combination to detect CIN2/CIN3
(n = 453)a.
CIN2/CIN3 Sensitivity (95% CI) Specificity (95% CI) AUC PPV (95% CI) NPV (95% CI) Test positivity
Pap
    ASCUS+ 102 92.7 (86.3–96.3) 49.3 (44.0–54.5) 0.71 37.0 (31.5–42.8) 95.5 (91.3–97.7) 60.9
    <ASCUS+ 8
Pap
    LSIL+ 94 85.5 (77.7–90.8) 67.3 (62.2–72.1) 0.76 45.6 (39.0–52.5) 93.5 (89.7–96.0) 45.5
    <LSIL+ 16
Pap
    HSIL+ 79 71.8 (62.8–79.4) 97.1 (94.7–98.4) 0.85 88.8 (80.5–93.8) 91.5 (88.2–93.9) 19.6
    <HSIL+ 31
VIA
    Positive 69 62.7 (53.4–71.2) 65.9 (60.7–70.7) 0.64 37.1 (30.5–44.2) 84.6 (79.8–88.5) 41.1
    Negative 41
HPV
    Positive 92 83.6 (75.6–89.4) 55.7 (50.4–60.9) 0.70 37.7 (31.9–43.9) 91.4 (86.8–94.5) 53.9
    Negative 18
VIA+HPV
    Positive 64 58.2 (48.8–67.0) 83.7 (79.4–87.2) 0.71 53.3 (44.4–62.0) 86.2 (82.1–89.5) 26.5
    Negative 46
VIA+Pap (ASCUS+)
    Positive 66 60.0 (50.7–68.7) 81.9 (77.5–85.6) 0.71 51.6 (43.0–60.1) 86.5 (82.3–89.8) 28.3
    Negative 44
VIA+Pap (LSIL+)
    Positive 64 58.2 (48.8–67.0) 88.0 (84.2–91.1) 0.73 61.0 (51.4–69.7) 86.8 (82.8–89.9) 23.2
    Negative 46
VIA+Pap (HSIL+)
    Positive 56 50.9 (41.7–60.1) 99.1 (97.5–99.7) 0.75 94.9 (86.1–98.3) 86.3 (82.5–89.3) 13.0
    Negative 54
HPV+Pap (ASCUS+)
    Positive 87 79.1 (70.6–85.6) 76.4 (71.6–80.6) 0.78 51.8 (44.3–59.2) 91.9 (88.2–94.6) 37.1
    Negative 23
HPV+Pap (LSIL+)
    Positive 81 73.6 (64.7–81.0) 84.3 (80.0–87.7) 0.79 60.0 (51.6–67.9) 90.9 (87.2–93.6) 29.8
    Negative 29
HPV+Pap (HSIL+)
    Positive 69 62.7 (53.4–71.2) 98.5 (96.6–99.4) 0.81 93.2 (85.1–97.1) 89.2 (85.7–91.9) 16.3
    Negative 41
VIA or HPV
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CIN2/CIN3 Sensitivity (95% CI) Specificity (95% CI) AUC PPV (95% CI) NPV (95% CI) Test positivity
    Positive 97 88.2 (80.8–93.0) 37.9 (32.9–43.1) 0.63 31.3 (26.4–36.7) 90.9 (85.1–94.6) 68.4
    Negative 13
VIA or Papb
    Positive 92 83.6 (75.6–89.4) 63.8 (58.6–68.8) 0.74 42.6 (36.2–49.3) 92.4 (88.3–95.2) 47.7
    Negative 18
Papb or HPV
    Positive 102 92.7 (86.3–96.3) 54.2 (48.9–59.4) 0.73 39.4 (33.6–45.4) 95.9 (92.1–97.9) 57.2
    Negative 8
ASCUS, atypical squamous cells of undetermined significance; AUC, area under the curve; CI, confidence interval; CIN, cervical intraepithelial
neoplasia; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; NPV,
negative predictive value; Pap, Papanicolau; PPV, positive predictive value; VIA, visual inspection with acetic acid. ‘+’ denotes both test positive
is positive. ‘or’ denotes either test positive is positive.
aOnly women with adequate results on all tests included.
b
Positive Pap smear defined as HSIL+.
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Table 4
Sensitivity and specificity of individual cervical cancer screening methods to detect CIN2/CIN3 compared by
CD4+ cell count, antiretroviral therapy duration and age (n = 453)a.
CD4+ cell count
≤350 cells/μl >350 cells/μl P
Sensitivity CIN2/CIN3 (n = 59) CIN2/CIN3 (n = 51)
Pap (ASCUS+) 91.5 94.1 0.7b
Pap (LSIL+) 84.7 86.3 0.8
Pap (HSIL+) 71.2 72.5 0.9
VIA 69.5 54.9 0.1
HPV 86.4 80.4 0.4
Specificity ≤CIN1 (n = 151) ≤CIN1 (n = 192)
Pap (ASCUS+) 47.0 51.0 0.5
Pap (LSIL+) 66.9 67.7 0.9
Pap (HSIL+) 95.4 98.4 0.1b
VIA 62.3 68.8 0.2
HPV 45.7 63.5 <0.001
ART duration
Off ART On ART <2 years On ART ≥2 years P
Sensitivity CIN2/CIN3 (n = 26) CIN2/CIN3 (n = 44) CIN2/CIN3 (n = 40)
Pap (ASCUS+) 92.3 95.5 90.0 0.6
Pap (LSIL+) 84.6 88.6 82.5 0.7
Pap (HSIL+) 65.4 79.5 67.5 0.3
VIA 61.5 68.2 57.5 0.4
HPV 92.3 81.8 80.0 0.4
Specificity ≤CIN1 (n = 91) ≤CIN1 (n = 110) ≤CIN1 (n = 142)
Pap (ASCUS+) 54.9 48.2 46.5 0.4
Pap (LSIL+) 73.6 65.5 64.8 0.3
Pap (HSIL+) 97.8 97.3 96.5 0.8
VIA 65.9 57.3 72.5 0.04
HPV 51.6 45.5 66.2 0.003
Age
<40 years ≥40 years P
Sensitivity CIN2/CIN3 (n = 55) CIN2/CIN3 (n = 55)
Pap (ASCUS+) 90.9 94.5 0.7b
Pap (LSIL+) 83.6 87.3 0.6
Pap (HSIL+) 72.7 70.9 0.8
VIA 78.2 47.3 <0.001
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Age
<40 years ≥40 years P
HPV 83.6 83.6 1.0
Specificity ≤CIN1 (n = 214) ≤CIN1 (n = 129)
Pap (ASCUS+) 48.1 51.2 0.6
Pap (LSIL+) 66.4 69.0 0.6
Pap (HSIL+) 98.6 94.6 0.05b
VIA 62.6 71.3 0.1
HPV 50.0 65.1 0.006
ART, antiretroviral therapy; ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HPV, human
papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; Pap, Papanicolau; VIA, visual
inspection with acetic acid.
aOnly women with adequate results on all tests included.
b
Fisher's exact test.
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Table 5
Univariate and multivariate logistic regression models of sensitivity of visual inspection with acetic acid,
specificity of Pap (HSIL+), specificity of visual inspection with acetic acid and specificity of human
papillomavirus.
Univariate model Multivariate modela
Sensitivity of VIA OR for positive test among CIN2/CIN3
(95% CI)
P OR for positive test among CIN2/CIN3
(95% CI)
P
Age ≥40 years 1.0 1.0
Age <40 years 4.00 (1.74–9.17) <0.001 3.95 (1.70–9.22) <0.001
CD4+ cell count >350 cells/μl 1.0 1.0
CD4+ cell count ≤350 cells/μl 1.87 (0.86–4.09) 0.1 1.75 (0.73–4.20) 0.2
On ART ≥2 years 1.0 1.0
Off ART 1.18 (0.43–3.24) 0.7 0.79 (0.26–2.40) 0.7
On ART <2 years 1.58 (0.65–3.86) 0.3 1.09 (0.40–2.98) 0.9
Univariate model Multivariate modela
Specificity of Pap (HSIL+) OR for negative test among ≤CIN1 (95%
CI)
P OR for negative test among ≤CIN1 (95%
CI)
P
Age ≥40 years 1.0 1.0
Age <40 years 4.04 (1.03–15.89) 0.05 3.56 (0.88–14.31) 0.07
CD4+ cell count >350 cells/μl 1.0 1.0
CD4+ cell count ≤350 cells/μl 0.33 (0.08–1.29) 0.1 0.33 (0.08–1.37) 0.1
On ART ≥2 years 1.0 1.0
Off ART 1.62 (0.31–8.56) 0.6 1.37 (0.25–7.49) 0.7
On ART <2 years 1.30 (0.30–5.57) 0.7 1.59 (0.35–7.16) 0.5
Univariate model Multivariate modela
Specificity of VIA OR for negative test among ≤CIN1 (95%
CI)
P OR for negative test among ≤CIN1 (95%
CI)
P
Age ≥40 years 1.0 1.0
Age <40 years 0.67 (0.42–1.08) 0.1 0.67 (0.41–1.08) 0.1
CD4+ cell count >350 cells/μl 1.0 1.0
CD4+ cell count ≤350 cells/μl 0.75 (0.48–1.17) 0.2 0.80 (0.50–1.27) 0.3
On ART ≥2 years 1.0 1.0
Off ART 0.73 (0.42–1.30) 0.3 0.80 (0.45–1.42) 0.8
On ART <2 years 0.51 (0.30–0.87) 0.01 0.55 (0.32–0.94) 0.03
Univariate model Multivariate modela
Specificity of HPV OR for negative test among ≤CIN1 (95%
CI)
P OR for negative test among ≤CIN1 (95%
CI)
P
Age ≥40 years 1.0 1.0
Age <40 years 0.54 (0.34–0.84) 0.006 0.51 (0.31–0.81) 0.005
CD4+ cell count >350 cells/μl 1.0 1.0
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Univariate model Multivariate modela
Specificity of HPV OR for negative test among ≤CIN1 (95%
CI)
P OR for negative test among ≤CIN1 (95%
CI)
P
CD4+ cell count ≤350 cells/μl 0.48 (0.31–0.75) <0.001 0.49 (0.31–0.77) 0.002
On ART ≥2 years 1.0 1.0
Off ART 0.55 (0.32–0.94) 0.03 0.62 (0.36–1.09) 0.1
On ART <2 years 0.43 (0.26–0.71) <0.001 0.51 (0.30–0.86) 0.01
ART, antiretroviral therapy; CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HSIL, high-grade
squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; OR, odds ratio; VIA, visual inspection with acetic acid.
aAll covariates listed are included in the multivariate model.
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